HK1161984A1 - 劑量方案 - Google Patents

劑量方案

Info

Publication number
HK1161984A1
HK1161984A1 HK12102508.7A HK12102508A HK1161984A1 HK 1161984 A1 HK1161984 A1 HK 1161984A1 HK 12102508 A HK12102508 A HK 12102508A HK 1161984 A1 HK1161984 A1 HK 1161984A1
Authority
HK
Hong Kong
Prior art keywords
edoxaban
dosage regime
regime
dosage
regime edoxaban
Prior art date
Application number
HK12102508.7A
Other languages
English (en)
Inventor
Takashi Abiko
Kazuhisa Uchiyama
Tomoko Motohashi
Tomoko Matsuda
Miharu Suda
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42268834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1161984(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of HK1161984A1 publication Critical patent/HK1161984A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
HK12102508.7A 2008-12-19 2012-03-13 劑量方案 HK1161984A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008323578 2008-12-19
PCT/JP2009/071016 WO2010071164A1 (ja) 2008-12-19 2009-12-17 活性化血液凝固第Ｘ因子(ＦＸａ)阻害剤

Publications (1)

Publication Number Publication Date
HK1161984A1 true HK1161984A1 (zh) 2012-08-17

Family

ID=42268834

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12102508.7A HK1161984A1 (zh) 2008-12-19 2012-03-13 劑量方案

Country Status (9)

Country Link
US (2) US20110275666A1 (zh)
EP (1) EP2374456B1 (zh)
JP (1) JPWO2010071164A1 (zh)
KR (1) KR20110104491A (zh)
CN (1) CN102325528A (zh)
ES (1) ES2600783T3 (zh)
HK (1) HK1161984A1 (zh)
TW (1) TW201026709A (zh)
WO (1) WO2010071164A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2644803T5 (es) 2007-03-29 2024-02-26 Daiichi Sankyo Co Ltd Composición farmacéutica
WO2010104106A1 (ja) 2009-03-13 2010-09-16 第一三共株式会社 光学活性なジアミン誘導体の製造方法
JP5692873B2 (ja) 2010-03-19 2015-04-01 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
CN103080078B (zh) 2010-07-02 2015-02-11 第一三共株式会社 光学活性二胺衍生物盐的制备方法
US20130158069A1 (en) 2011-12-14 2013-06-20 Daiichi Sankyo Company, Limited Preventive and/or therapeutic agent for thromboembolism in thromboembolism patient with severe renal impairment
CN103936763B (zh) * 2013-01-18 2017-10-31 中国科学院上海药物研究所 噁唑烷酮类化合物及其制备方法和用途
WO2015028919A1 (en) * 2013-08-29 2015-03-05 Daiichi Sankyo Company, Limited Agent for the treatment and prevention of cancer
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
EP3744320A1 (en) 2019-05-29 2020-12-02 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising edoxaban
WO2021110076A1 (zh) * 2019-12-04 2021-06-10 深圳信立泰药业股份有限公司 草酰胺类衍生物、其制备方法及其在医药上的应用
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
CN116052837B (zh) * 2022-11-28 2023-11-10 北京医院 一种血液透析中抗凝剂用量的评估方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1405852B9 (en) 2001-06-20 2013-03-27 Daiichi Sankyo Company, Limited Diamine derivatives
KR20050110612A (ko) 2002-12-25 2005-11-23 다이이찌 세이야꾸 가부시기가이샤 디아민 유도체
ES2644803T5 (es) * 2007-03-29 2024-02-26 Daiichi Sankyo Co Ltd Composición farmacéutica

Also Published As

Publication number Publication date
CN102325528A (zh) 2012-01-18
JPWO2010071164A1 (ja) 2012-05-31
US20110275666A1 (en) 2011-11-10
US20130184308A1 (en) 2013-07-18
EP2374456A4 (en) 2012-07-04
EP2374456B1 (en) 2016-08-03
ES2600783T3 (es) 2017-02-10
TW201026709A (en) 2010-07-16
KR20110104491A (ko) 2011-09-22
WO2010071164A1 (ja) 2010-06-24
EP2374456A1 (en) 2011-10-12

Similar Documents

Publication Publication Date Title
HK1161984A1 (zh) 劑量方案
IL237391A0 (en) Pharmaceutical combination
GB0909680D0 (en) Dosage form
ZA201400310B (en) Solid dosage form
ZA201006029B (en) Pharmaceutical dosage form
HK1167809A1 (en) Oxidation-stabilized tamper-resistant dosage form
ZA201005015B (en) Solid pharmaceutical dosage form
PL2381987T3 (pl) Automatyczne wstrzykiwacze
AP3250A (en) Tablets for combination therapy
ZA200903858B (en) Pharmaceutical dosage form
IL210393A0 (en) Administration regime for nitrocatechols
HK1152640A1 (en) Pharmaceutical combination
GB0803054D0 (en) Medicament
HU0800414D0 (en) Pharmaceutical combination
GB0802576D0 (en) Dosage form
GB0704123D0 (en) Dosage form
GB0803395D0 (en) Medicament
GB201007429D0 (en) Treatment regime
GB201007488D0 (en) Treatment regime
GB0808403D0 (en) Lhrh
GB0903318D0 (en) Medicament
GB0901902D0 (en) Medicament
GB0818712D0 (en) Therapeutic substances
GB0810952D0 (en) Therapeutic substances
GB0804377D0 (en) Therapeutic substances